KPC Pharmaceuticals,Inc. (SHA:600422)

Market Cap	6.28B -47.5%
Revenue (ttm)	5.80B -28.2%
Net Income	117.67M -80.6%
EPS	0.16 -80.9%
Shares Out	756.98M
PE Ratio	53.52
Forward PE	19.88
Dividend	0.18 (2.12%)
Ex-Dividend Date	Jul 30, 2025

Volume	7,848,800
Open	8.51
Previous Close	8.50
Day's Range	8.28 - 8.54
52-Week Range	8.29 - 15.91
Beta	-0.10
Analysts	Strong Buy
Price Target	16.15 (+94.58%)
Earnings Date	Aug 18, 2026

About KPC Pharmaceuticals,Inc.

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as well as engages in the wholesale and retail of medicines and equipment. ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 5,072
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600422

Financial Performance

In 2025, KPC Pharmaceuticals,Inc.'s revenue was 6.58 billion, a decrease of -21.74% compared to the previous year's 8.40 billion. Earnings were 349.94 million, a decrease of -46.00%.